How do you prevent muscle loss on a GLP-1?

How much of GLP-1 weight loss is lean tissue?

Roughly 38 percent of total weight lost can come from lean body mass, not fat, according to a body composition substudy of the STEP 1 trial of Wegovy (semaglutide 2.4 mg once weekly) in 1,961 adults with obesity over 68 weeks. In the DXA substudy, fat mass fell 19.3 percent while lean mass fell approximately 9.7 percent from baseline. Rubino et al., Obesity, 2021. A 2025 joint advisory from four professional societies confirmed the approximately 38 percent lean fraction of total weight reduction drawn from those same STEP 1 data. Mozaffarian et al., Obesity Pillars, 2025.

For context, typical calorie-restriction diets without medication produce lean mass losses of around 20 to 25 percent of total weight lost. The GLP-1 figure is higher, though the absolute fat mass lost (roughly 10 kg on average in STEP 1) still represents a substantial improvement in overall body composition.

These body composition data apply to Wegovy, an FDA-approved weight-management medication. Compounded semaglutide and compounded tirzepatide are not FDA-approved and have not been studied in equivalent body composition trials, so whether their lean mass effects are similar is not established by published clinical evidence.

A 2026 observational study called SEMALEAN tracked 200 adults on semaglutide over 12 months using DXA scans. Although absolute lean mass fell by about 3 kg through the first seven months, the proportion of lean mass relative to total body weight increased, and the prevalence of sarcopenic obesity dropped from 49 percent to 33 percent of participants. Alissou et al., Diabetes, Obesity and Metabolism, 2026. Lean tissue loss is real, but it tends to be modest compared to fat loss and can be reduced further with deliberate habits. See what to expect in your first 90 days on a GLP-1 for a week-by-week account of how weight and composition typically change.

Why do GLP-1 medications reduce lean mass alongside fat?

GLP-1 receptor agonists suppress appetite by slowing gastric emptying and activating satiety centers in the brain. That appetite suppression is their primary mechanism, but it also means many people consume far fewer calories than their bodies need, including far less protein. When protein intake falls and calorie deficit deepens, the body increasingly draws on muscle protein as a fuel source, a process called muscle protein catabolism.

This is not unique to GLP-1 medications. Any rapid calorie deficit, whether from a strict diet, bariatric surgery, or medication, can accelerate lean tissue loss. What makes the GLP-1 context distinctive is how quickly and deeply appetite is suppressed, sometimes outpacing a person's ability to adjust their diet intentionally.

The degree of lean mass loss also varies by sex. A 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society modeled GLP-1 weight loss outcomes and found that lean mass loss represents roughly 10 to 15 percent of total weight reduction in women and 20 to 25 percent in men in the absence of structured strength training. Mozaffarian et al., Obesity Pillars, 2025. Men who skip resistance exercise while on a GLP-1 may lose a disproportionately higher fraction of muscle. Both protein intake and resistance training are variables within a person's control, and both matter.

Who is most at risk for lean mass loss on a GLP-1?

Older adults face the steepest risk. Sarcopenia, the age-related loss of muscle mass and strength, already affects an estimated 10 to 16 percent of adults aged 60 and older, and that figure can reach 47 percent in those with comorbidities such as type 2 diabetes. Prokopidis et al., British Journal of Pharmacology, 2025. A 24-month retrospective cohort study of 220 adults aged 65 and older found that semaglutide was associated with accelerated loss of appendicular skeletal muscle mass, with women losing an average of 0.39 kg per square meter and men 0.26 kg per square meter over the study period, and gait speed declining significantly in both groups. Ren et al., Drug Design, Development and Therapy, 2025.

Beyond age, four other groups deserve extra attention:

• People who are already sedentary. Those who do little or no resistance training before starting a GLP-1 have no training stimulus protecting lean tissue during the calorie deficit.
• Those with low baseline muscle mass. People with a low muscle-to-fat ratio lose a higher proportion of lean tissue per kilogram of overall weight lost.
• Anyone eating below 60 grams of protein per day. Severely inadequate protein removes the primary nutritional defense against catabolism.
• People losing weight rapidly. Faster total weight loss is consistently associated with a higher lean fraction lost in the research literature.

How much protein do you need each day on a GLP-1?

The standard Recommended Dietary Allowance for protein is 0.8 grams per kilogram of body weight per day, a floor designed to prevent deficiency in sedentary healthy adults. That baseline is too low for anyone actively losing weight on a GLP-1. The 2025 joint advisory from four professional societies recommends 1.2 to 1.6 grams of protein per kilogram of adjusted body weight per day during active weight reduction, rising to as high as 2.0 g/kg for those combining GLP-1 therapy with structured strength training. Mozaffarian et al., Obesity Pillars, 2025.

For practical daily planning, the same advisory offers an absolute target of 80 to 120 grams of protein per day, which many people find easier to track than weight-adjusted calculations.

A concrete example: a person weighing 90 kg (about 200 lbs) aiming for 1.4 g/kg needs roughly 126 grams of protein daily. That translates to approximately four servings of around 30 grams each, achievable through foods such as eggs, Greek yogurt, cottage cheese, chicken breast, canned fish, and legumes.

Protein should be spread across three or four meals rather than consumed in one sitting. Evidence on muscle protein synthesis supports distributing protein intake across three or four meals rather than concentrating it in one sitting, as this keeps the anabolic stimulus active across more hours of the day. Spreading intake throughout the day keeps the anabolic signal active over more hours, rather than creating a single large spike.

How to eat enough protein when appetite is suppressed

The appetite suppression from GLP-1 therapy is also the main barrier to hitting protein targets. People who once felt hungry every few hours may go six to eight hours without any desire to eat. Skipping meals is easy under these conditions, but it almost always leads to protein shortfalls that compound over days and weeks.

A protein-first approach at each meal is the most practical adjustment. Eating protein before grains, vegetables, or fats ensures that when appetite cuts off early, the most important macronutrient has already been consumed. A plate that starts with chicken and ends with rice protects lean mass better than one assembled in reverse order.

Specific strategies for low-appetite days:

• Liquid protein sources. Greek yogurt drinks, kefir, cottage cheese blended into smoothies, and protein shakes are easier to consume than solid meals when nausea or rapid fullness arrives. A 30-gram protein shake takes about a minute to drink.
• Calorie-dense protein foods. Hard-boiled eggs, edamame, canned salmon, and string cheese deliver high protein in small volumes.
• Scheduled eating. Hunger cues are suppressed, so relying on them to prompt eating does not work. Setting an alarm every four to five hours keeps protein intake consistent even when appetite does not signal a meal.
• A protein-rich first meal of the day. Research on protein distribution shows that a protein-heavy morning meal supports net protein balance throughout the day better than back-loading protein at dinner.

Why resistance training is the core signal for muscle retention

Eating enough protein supplies the building blocks for muscle, but resistance training provides the biological signal telling the body to use those building blocks rather than break down existing tissue. When a muscle is placed under mechanical load through free weights, machines, resistance bands, or bodyweight exercises, it activates a biochemical pathway called mTORC1 that drives muscle protein synthesis and suppresses protein degradation.

Without that mechanical signal, even adequate protein intake cannot fully prevent catabolism during a sustained calorie deficit. The reverse is equally true: lifting weights without sufficient protein provides the stimulus but lacks the substrate to execute it.

The two strategies work together, not independently. The 2025 joint advisory summarized a study in which adults on GLP-1 therapy who received structured resistance training education and individualized protein guidance lost approximately 13 percent of body weight over six months but experienced only about 3 percent lean mass loss (Mozaffarian et al., Obesity Pillars, 2025; the primary study should be independently cited here). For comparison, the STEP 1 trial of Wegovy (semaglutide 2.4 mg, an FDA-approved medication), where participants followed general lifestyle guidance without a supervised resistance training protocol, showed a lean fraction of approximately 38 percent. These figures come from different studies with different populations, protocols, durations, and endpoints; the contrast illustrates directional magnitude, not a controlled head-to-head result. Compounded semaglutide is not FDA-approved and has not been evaluated in equivalent trials.

Cardio, including walking, cycling, and swimming, supports cardiovascular health and contributes to calorie expenditure, but it does not send the same muscle-retention signal as progressive resistance training. Both have a role in an overall fitness plan, but the priority for lean mass preservation is the weight room, not the treadmill.

How often should you train, and what type of exercise?

The 2025 joint advisory recommends at least three resistance training sessions per week combined with at least 150 minutes of moderate-intensity aerobic exercise weekly. Mozaffarian et al., Obesity Pillars, 2025. This aligns with the American College of Sports Medicine's general resistance training guidelines for adults maintaining or building muscle during weight loss.

Compound movements, those involving multiple joints and muscle groups simultaneously, are the most time-efficient choice. Squats, deadlifts, hip hinges, rows, overhead presses, and push-up variations engage large amounts of muscle mass per set and produce the strongest anabolic stimulus per unit of training time. Progressive overload, adding small amounts of weight, reps, or sets every one to two weeks, prevents adaptation and keeps the muscle-building signal elevated as fitness improves.

For people new to strength training or starting from a deconditioned baseline, bodyweight and resistance band exercises are effective entry points that can be progressed systematically before adding external load.

What to track beyond the number on the scale

Scale weight alone is an unreliable guide to body composition change on a GLP-1. Someone who loses 10 kilograms could have lost 6 kg of fat and 4 kg of lean tissue, or 9 kg of fat and 1 kg of lean tissue. The scale cannot distinguish between these two very different outcomes, and the strategies needed to address each situation are completely different.

Practical markers that give a clearer picture of lean mass status:

• Handgrip strength. Handgrip dynamometry is a validated proxy for whole-body skeletal muscle strength and is used routinely in sarcopenia screening. A declining grip over weeks or months is an early warning sign of disproportionate lean mass loss, independent of total body weight change. The SEMALEAN study tracked handgrip strength and found it improved by an average of 3.7 kg after seven months of semaglutide treatment with lifestyle support. Alissou et al., 2026.
• Performance benchmarks. Tracking how many pushups, goblet squat reps with a fixed load, or single-leg balance seconds can be completed gives concrete, repeatable data on functional muscle capacity.
• Walking speed. Gait speed over a short course is another clinically validated marker of muscle function that is easy to measure at home with a stopwatch.
• Waist circumference. Declining waist circumference alongside weight loss is a sign that visceral fat is being preferentially reduced.
• DXA scan. For people at high risk of lean mass loss, including adults over 65 and those with low baseline muscle mass, a DXA body composition scan at baseline and at six months provides the most direct measurement of fat versus lean change over time.

When does involving a registered dietitian make sense?

A registered dietitian adds the most value when standard self-management strategies are not enough to protect lean mass. A striking gap in the existing evidence: the 2025 joint advisory reviewed 12 GLP-1 clinical trials and found that only 3 of the 12 included a registered dietitian as part of the care team. Mozaffarian et al., Obesity Pillars, 2025. That absence may partly explain why lean mass losses in trials tend to be higher than what structured nutrition counseling achieves in clinical practice.

Situations where a dietitian referral is especially worth considering:

• Age 65 and older. Anabolic resistance, the reduced ability of older muscle to respond to protein, means older adults need higher absolute protein intakes and more precise meal timing to achieve the same muscle-protective benefit that younger adults get from the same intake.
• Inability to reach protein targets after four to six weeks. If persistent nausea, food aversions, or reduced appetite make 80 grams of daily protein feel unachievable, a dietitian can identify protein sources and meal timing strategies fitted to that individual's tolerances and preferences.
• History of disordered eating. Severe calorie restriction during GLP-1 therapy can interact unpredictably with disordered eating patterns, and a dietitian can coordinate care with the treating mental health provider.
• Micronutrient concerns. Reduced calorie intake raises the risk of deficiencies in vitamin B12, iron, folate, and calcium, all documented in GLP-1 user populations. A dietitian can guide supplement use and food choices to address these gaps safely.

Any change in nutrition, supplementation, or exercise should be discussed with a licensed clinician who knows the individual's full medical history and treatment plan.